A Mechanistic Model for Predicting Cell Surface Presentation of Competing Peptides by MHC Class I Molecules

Major histocompatibility complex-I (MHC-I) molecules play a central role in the immune response to viruses and cancers. They present peptides on the surface of affected cells, for recognition by cytotoxic T cells. Determining which peptides are presented, and in what proportion, has profound implications for developing effective, medical treatments. However, our ability to predict peptide presentation levels is currently limited. Existing prediction algorithms focus primarily on the binding affinity of peptides to MHC-I, and do not predict the relative abundance of individual peptides on the surface of antigen-presenting cells in situ which is a critical parameter for determining the strength and specificity of the ensuing immune response. Here, we develop and experimentally verify a mechanistic model for predicting cell-surface presentation of competing peptides. Our approach explicitly models key steps in the processing of intracellular peptides, incorporating both peptide binding affinity and intracellular peptide abundance. We use the resulting model to predict how the peptide repertoire is modified by interferon-γ, an immune modulator well known to enhance expression of antigen processing and presentation proteins.

[1]  G. Merlino,et al.  The Two Faces of Interferon-γ in Cancer , 2011, Clinical Cancer Research.

[2]  L. Kaer,et al.  Impaired assembly yet normal trafficking of MHC class I molecules in Tapasin mutant mice. , 2000, Immunity.

[3]  Drew M. Pardoll,et al.  The blockade of immune checkpoints in cancer immunotherapy , 2012, Nature Reviews Cancer.

[4]  Georg Seelig,et al.  A spatially localized architecture for fast and modular DNA computing. , 2017, Nature nanotechnology.

[5]  Luca Cardelli,et al.  A Peptide Filtering Relation Quantifies MHC Class I Peptide Optimization , 2011, PLoS Comput. Biol..

[6]  Hoon Kim,et al.  Monte Carlo Statistical Methods , 2000, Technometrics.

[7]  M. Hollingsworth,et al.  Tapasin Decreases Immune Responsiveness to a Model Tumor Antigen , 2004, Journal of Clinical Immunology.

[8]  T. Elliott,et al.  Tapasin shapes immunodominance hierarchies according to the kinetic stability of peptide – MHC class I complexes , 2008, European journal of immunology.

[9]  L. Jensen,et al.  Mass Spectrometry of Human Leukocyte Antigen Class I Peptidomes Reveals Strong Effects of Protein Abundance and Turnover on Antigen Presentation* , 2015, Molecular & Cellular Proteomics.

[10]  Lloyd J. Old,et al.  The roles of IFNγ in protection against tumor development and cancer immunoediting , 2002 .

[11]  T. Elliott,et al.  CD8+ T-cell cross-competition is governed by peptide–MHC class I stability , 2011, European journal of immunology.

[12]  M. Garcia-Peydró,et al.  Quantitative and Qualitative Influences of Tapasin on the Class I Peptide Repertoire1 , 2001, The Journal of Immunology.

[13]  Ilan Beer,et al.  The Turnover Kinetics of Major Histocompatibility Complex Peptides of Human Cancer Cells* , 2006, Molecular & Cellular Proteomics.

[14]  J. Yewdell,et al.  The exception that reinforces the rule: crosspriming by cytosolic peptides that escape degradation. , 2008, Immunity.

[15]  E. Caron,et al.  The MHC class I peptide repertoire is molded by the transcriptome , 2008, The Journal of experimental medicine.

[16]  Markus Müller,et al.  High-throughput and Sensitive Immunopeptidomics Platform Reveals Profound Interferonγ-Mediated Remodeling of the Human Leukocyte Antigen (HLA) Ligandome* , 2017, Molecular & Cellular Proteomics.

[17]  Manoj Bhasin,et al.  Analysis and prediction of affinity of TAP binding peptides using cascade SVM , 2004, Protein science : a publication of the Protein Society.

[18]  T. Rau,et al.  Loss of tapasin correlates with diminished CD8+ T-cell immunity and prognosis in colorectal cancer , 2015, Journal of Translational Medicine.

[19]  A. Goldberg,et al.  Re-examining class-I presentation and the DRiP hypothesis. , 2014, Trends in immunology.

[20]  T. Elliott,et al.  Selector function of MHC I molecules is determined by protein plasticity , 2015, Scientific Reports.

[21]  Michelle S. Scott,et al.  A Quantitative Spatial Proteomics Analysis of Proteome Turnover in Human Cells* , 2011, Molecular & Cellular Proteomics.

[22]  Charlotte M. Deane,et al.  Rapid, Precise, and Reproducible Prediction of Peptide-MHC Binding Affinities from Molecular Dynamics That Correlate Well with Experiment. , 2015, Journal of chemical theory and computation.

[23]  James McCluskey,et al.  Optimization of the MHC class I peptide cargo is dependent on tapasin. , 2002, Immunity.

[24]  Peter V. Coveney,et al.  The Role of Multiscale Protein Dynamics in Antigen Presentation and T Lymphocyte Recognition , 2017, Front. Immunol..

[25]  T. Elliott,et al.  Absence of Tapasin Alters Immunodominance against a Lymphocytic Choriomeningitis Virus Polytope , 2009, The Journal of Immunology.

[26]  Akira Hattori,et al.  An IFN-γ–induced aminopeptidase in the ER, ERAP1, trims precursors to MHC class I–presented peptides , 2002, Nature Immunology.

[27]  Ruedi Aebersold,et al.  Analysis of Major Histocompatibility Complex (MHC) Immunopeptidomes Using Mass Spectrometry. , 2015, Molecular & cellular proteomics : MCP.

[28]  S. Stevanović,et al.  TAPBPR bridges UDP-glucose:glycoprotein glucosyltransferase 1 onto MHC class I to provide quality control in the antigen presentation pathway , 2017, eLife.

[29]  Anthony W. Purcell,et al.  Kinetics of Antigen Expression and Epitope Presentation during Virus Infection , 2013, PLoS pathogens.

[30]  Ö. Türeci,et al.  Targeting the Heterogeneity of Cancer with Individualized Neoepitope Vaccines , 2016, Clinical Cancer Research.

[31]  S. Brunak,et al.  Prediction of proteasome cleavage motifs by neural networks. , 2002, Protein engineering.

[32]  J. Yewdell,et al.  Confronting complexity: real-world immunodominance in antiviral CD8+ T cell responses. , 2006, Immunity.

[33]  Bjoern Peters,et al.  Naive Precursor Frequencies and MHC Binding Rather Than the Degree of Epitope Diversity Shape CD8+ T Cell Immunodominance1 , 2008, The Journal of Immunology.

[34]  R. Schreiber,et al.  Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice , 1998 .

[35]  Peter V Coveney,et al.  Host genotype and time dependent antigen presentation of viral peptides: predictions from theory , 2017, Scientific Reports.

[36]  Anthony W. Purcell,et al.  Constitutive and Inflammatory Immunopeptidome of Pancreatic β-Cells , 2012, Diabetes.

[37]  Philip E. Bourne,et al.  Immune epitope database analysis resource , 2012, Nucleic Acids Res..

[38]  Ilan Beer,et al.  The Effect of Proteasome Inhibition on the Generation of the Human Leukocyte Antigen (HLA) Peptidome* , 2013, Molecular & Cellular Proteomics.

[39]  J. Drijfhout,et al.  Cross-presentation by intercellular peptide transfer through gap junctions , 2005, Nature.

[40]  K. Parker,et al.  Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. , 1994, Journal of immunology.

[41]  Arie Admon,et al.  The nature and extent of contributions by defective ribosome products to the HLA peptidome , 2014, Proceedings of the National Academy of Sciences.

[42]  W. Gillanders,et al.  Personalized cancer vaccines: Targeting the cancer mutanome. , 2017, Vaccine.

[43]  George Coukos,et al.  Mass spectrometry-based antigen discovery for cancer immunotherapy. , 2016, Current opinion in immunology.

[44]  T. Elliott,et al.  Differential Suppression of Tumor-Specific CD8+ T Cells by Regulatory T Cells , 2010, The Journal of Immunology.

[45]  J. Yewdell,et al.  Translating DRiPs: MHC class I immunosurveillance of pathogens and tumors , 2014, Journal of leukocyte biology.

[46]  J. Yewdell,et al.  Localization, quantitation, and in situ detection of specific peptide-MHC class I complexes using a monoclonal antibody. , 1997, Immunity.

[47]  T. Elliott,et al.  Tapasin enhances MHC class I peptide presentation according to peptide half-life. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[48]  T. Elliott,et al.  The cell biology of major histocompatibility complex class I assembly: towards a molecular understanding. , 2010, Tissue antigens.

[49]  A. Diehl,et al.  Impaired immune responses and altered peptide repertoire in tapasin-deficient mice , 2000, Nature Immunology.

[50]  Özlem Türeci,et al.  Immunomic, genomic and transcriptomic characterization of CT26 colorectal carcinoma , 2013, BMC Genomics.

[51]  J. Luke,et al.  Mechanistic and pharmacologic insights on immune checkpoint inhibitors , 2017, Pharmacological research.

[52]  J. Yewdell,et al.  Compartmentalized MHC class I antigen processing enhances immunosurveillance by circumventing the law of mass action , 2010, Proceedings of the National Academy of Sciences.

[53]  R. Schreiber,et al.  IFN unresponsiveness in LNCaP cells due to the lack of JAK1 gene expression. , 2005, Cancer research.

[54]  Morten Nielsen,et al.  Gapped sequence alignment using artificial neural networks: application to the MHC class I system , 2016, Bioinform..

[55]  J. Leunissen,et al.  The Human Leukocyte Antigen–presented Ligandome of B Lymphocytes* , 2013, Molecular & Cellular Proteomics.

[56]  A. Chakraborty,et al.  T cell sensing of antigen dose governs interactive behavior with dendritic cells and sets a threshold for T cell activation , 2008, Nature Immunology.

[57]  Ilka Hoof,et al.  Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome , 2015, PloS one.

[58]  J. Yewdell,et al.  Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? , 1996, Journal of immunology.